Alzheimer's is a gradual condition that begins with modest memory loss and may proceed to loss of capacity to converse and respond to the surroundings. Scientists have yet to completely grasp what causes Alzheimer's disease, which is rather a combination of circumstances that influence each individual differently.

But a new research may shed light on the actual reason, giving hope and facilitating the tracing of the disease symptoms at earlier stages, thus giving additional time for patients to learn how to comply with its symptoms. 

According to a study presented at the International Clinical Trials on Alzheimer's Disease (CTAD) conference, the protein that triggers Alzheimer's symptoms may now be identified.

The research indicated that a blood test could be used in a clinical trial to identify those who are more likely to have brain amyloid, a protein highly contributive to the development Alzheimer's symptoms.

Usually, Alzheimer's disease is diagnosed using a positron emission tomography (PET) scan method to evaluate the build-up of amyloid plaques in the brain. Now the research found that a blood test called PrecivityADTM, created by C2N Diagnostics, is 81% accurate in predicting the levels of this build-up.

The blood test is a promising method to identify a patient's likelihood of having amyloid buildup in the brain, allowing for quicker findings at a lower cost than PET scans. Moreover, the blood test will be utilized for the first time in the AHEAD Study, a clinical trial with the objective of avoiding Alzheimer's disease symptoms.